APOBEC3A/B deletion polymorphism and cancer risk

Carcinogenesis

Volumn 39, Issue 2, 2018, Pages 118-124

  Gansmo, Liv B ^a,b   Romundstad, Paal ^c   Hveem, Kristian ^c   Vatten, Lars ^c   Nik Zainal, Serena ^d,e   Lønning, Per Eystein ^a,b   Knappskog, Stian ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^d WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^e ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B MRNA EDITING ENZYME CATALYTIC POLYPEPTIDE LIKE; APOLIPOPROTEIN B MRNA EDITING ENZYME CATALYTIC POLYPEPTIDE LIKE 3A; APOLIPOPROTEIN B MRNA EDITING ENZYME CATALYTIC POLYPEPTIDE LIKE 3B; UNCLASSIFIED DRUG; APOBEC3A PROTEIN, HUMAN; APOBEC3B PROTEIN, HUMAN; CYTIDINE DEAMINASE; MINOR HISTOCOMPATIBILITY ANTIGEN; PROTEIN;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER INCIDENCE; CANCER PATIENT; CANCER RISK; CASE CONTROL STUDY; COHORT ANALYSIS; COLON CANCER; COLON CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENE DELETION; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; GERMLINE MUTATION; HUMAN; LUNG CANCER; LUNG CARCINOGENESIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MINOR (PERSON); MOLECULAR PATHOLOGY; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; CAUCASIAN; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; NEOPLASM; NORWAY; RISK FACTOR;

ADULT; AGED; CASE-CONTROL STUDIES; CYTIDINE DEAMINASE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MINOR HISTOCOMPATIBILITY ANTIGENS; NEOPLASMS; NORWAY; POLYMORPHISM, GENETIC; PROTEINS; RISK FACTORS;

EID: 85044437335     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgx131     Document Type: Article

References (33)

1. Alexandrov, L.B. et al. (2013) Signatures of mutational processes in human cancer. Nature, 500, 415-421
2. Helleday, T. et al. (2014) Mechanisms underlying mutational signatures in human cancers. Nat. Rev. Genet., 15, 585-598
3. Roberts, S.A. et al. (2014) Hypermutation in human cancer genomes: footprints and mechanisms. Nat. Rev. Cancer, 14, 786-800
4. Saraconi, G. et al. (2014) The RNA editing enzyme APOBEC1 induces somatic mutations and a compatible mutational signature is present in esophageal adenocarcinomas. Genome Biol., 15, 417
5. Swanton, C. et al. (2015) APOBEC enzymes: mutagenic fuel for cancer evolution and heterogeneity. Cancer Discov., 5, 704-712
6. Burns, M.B. et al. (2013) Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat. Genet., 45, 977-983
7. Chan, K. et al. (2015) An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers. Nat. Genet., 47, 1067-1072
8. Petit, V. et al. (2009) Powerful mutators lurking in the genome. Philos. Trans. R. Soc. Lond. B. Biol. Sci., 364, 705-715
9. Jarmuz, A. et al. (2002) An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics, 79, 285-296
10. Navaratnam, N. et al. (2006) An overview of cytidine deaminases. Int. J. Hematol., 83, 195-200
11. Conticello, S.G. (2008) The AID/APOBEC family of nucleic acid mutators. Genome Biol., 9, 229
12. Mussil, B. et al. (2013) Human APOBEC3A isoforms translocate to the nucleus and induce DNA double strand breaks leading to cell stress and death. PLoS One, 8, e73641
13. Suspène, R. et al. (2011) Somatic hypermutation of human mitochondrial and nuclear DNA by APOBEC3 cytidine deaminases, a pathway for DNA catabolism. Proc. Natl. Acad. Sci. USA., 108, 4858-4863
14. Shinohara, M. et al. (2012) APOBEC3B can impair genomic stability by inducing base substitutions in genomic DNA in human cells. Sci. Rep., 2, 806
15. Nik-Zainal, S. et al. (2014) Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer. Nat. Genet., 46, 487-491
16. Kidd, J.M. et al. (2007) Population stratification of a common APOBEC gene deletion polymorphism. PLoS Genet., 3, e63
17. Caval, V. et al. (2014) A prevalent cancer susceptibility APOBEC3A hybrid allele bearing APOBEC3B 3'UTR enhances chromosomal DNA damage. Nat. Commun., 5, 5129
18. Long, J. et al. (2013) A common deletion in the APOBEC3 genes and breast cancer risk. J. Natl. Cancer Inst., 105, 573-579
19. Qi, G. et al. (2014) APOBEC3 deletion polymorphism is associated with epithelial ovarian cancer risk among Chinese women. Tumour Biol., 35, 5723-5726
20. Wen, W.X. et al. (2016) Germline APOBEC3B deletion is associated with breast cancer risk in an Asian multi-ethnic cohort and with immune cell presentation. Breast Cancer Res., 18, 56
21. Xuan, D. et al. (2013) APOBEC3 deletion polymorphism is associated with breast cancer risk among women of European ancestry. Carcinogenesis, 34, 2240-2243
22. Göhler, S. et al. (2016) Impact of functional germline variants and a deletion polymorphism in APOBEC3A and APOBEC3B on breast cancer risk and survival in a Swedish study population. J. Cancer Res. Clin. Oncol., 142, 273-276
23. Naess, O. et al. (2008) Cohort profile: cohort of Norway (CONOR). Int. J. Epidemiol., 37, 481-485
24. Gansmo, L.B. et al. (2015) Influence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon. Int. J. Cancer, 137, 96-103
25. Gansmo, L.B. et al. (2015) MDM4 SNP34091 (rs4245739) and its effect on breast-, colon-, lung-, and prostate cancer risk. Cancer Med., 4, 1901-1907
26. Gansmo, L.B. et al. (2016) Associations between the MDM2 promoter P1 polymorphism del1518 (rs3730485) and incidence of cancer of the breast, lung, colon and prostate. Oncotarget, 7, 28637-28646
27. Helwa, R. et al. (2016) MDM2 promoter SNP55 (rs2870820) affects risk of colon cancer but not breast-, lung-, or prostate cancer. Sci. Rep., 6, 33153
28. Middlebrooks, C.D. et al. (2016) Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBECsignature mutations in tumors. Nat. Genet., 48, 1330-1338
29. Genomes Project, C., et al. (2015) A global reference for human genetic variation. Nature, 526, 68-74
30. Bond, G.L. et al. (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell, 119, 591-602
31. Economopoulos, K.P. et al. (2010) Differential effects of MDM2 SNP309 polymorphism on breast cancer risk along with race: a meta-analysis. Breast Cancer Res. Treat., 120, 211-216
32. Knappskog, S. et al. (2011) The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians. Cancer Cell, 19, 273-282
33. Knappskog, S. et al. (2014) Population distribution and ancestry of the cancer protective MDM2 SNP285 (rs117039649). Oncotarget, 5, 8223-8234